Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1992-10-15
1995-07-25
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514904, 514910, A61K 31135
Patent
active
054362725
ABSTRACT:
N,N-dimethyl-1-[ 1-(4-chlorophenyl)cyclobutyl] -3-methylbutylamine hydrochloride is used in the treatment of obesity in humans.
REFERENCES:
patent: 4443449 (1984-04-01), Jeffery et al.
patent: 4522828 (1985-06-01), Jeffery et al.
patent: 4746680 (1988-05-01), Jeffery et al.
patent: 4767790 (1988-08-01), Jeffery et al.
patent: 4806570 (1989-02-01), Jeffery et al.
patent: 4814352 (1989-03-01), Jeffery et al.
King et al 1988 110CA:33617z.
Buckett et al 1988 109CA:204745a.
Wurtman et al J. J. D-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects. Int'l Journal of Obesity vol. 8, suppl. 1, 79-84 (1984).
Rockwell et al, W. J. K. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med. J. 76:1407-1412, (1983).
Fuller, R. W. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders. J. Clin. Psychiatry 47 (Suppl. 4): 4-8 (1986).
Paykel et al, E.S. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br. J. Psychiatry 123: 501-507 (1973).
Nakra et al, B.R.S. Amitriptyline and weight gain: a biochemical and endrocrinological study. Current Med. Res. Opin. 4: 602-606 (1977).
Asberg et al, M. Therapeutic effects of serotonin uptake inhibitors in depression. J. Clin. Psychiatry 47 (Suppl. 4): 23-35. (1986).
Angel et al., "Anorectic Activities of Serotonin Uptake Inhibitors: Correlation With Their Potencies At Inhibiting Serotonin Uptake In Vivo and .sup.3 H-Mazindol Binding In Vitro;" Life Sciences, vol. 43, pp. 651-658; 1988.
Blundell, J. E., "Serotonin and Appetite", Neuropharmacology, vol. 23, No. 12B, pp. 1537-1551, 1984.
Luscombe et al., British J. Pharmacol., 1987, p. 575 (Proceedings Supplement) presented at British Pharmacol. Society, Oxford, Sep. 9-11, 1987, "Down-Regulation of Rat Cortical .beta.-Adrenoceptors by the Putative Antidepressant BTS 54 524: Contribution of Metabolites".
Wynne et al., Abstracts, III World Conf. on Clin. Pharmacol. & Therapeutics, Stockholm, Jul. 27-Aug. 1, 1986, "The Effect of BTS 54 524, A Novel Antidepressant, on Monoamine Reuptake and Cardiovascular Parameters in Man".
Buckett et al., Collegium International Neuro-Psychopharmacologicum Dec. 14-17, 1986, p. 251, "The Pharmacology of BTS 54 524, a New Antidepressant Which Induces Rapid Noradrenergic Down-Regulation".
Buckett et al., British Pharmacol. Soc., Oral Communication, Dec. 19, 1986 "the Putative Antidepressant BTS 54 524 Rapidly and Potentially Down-Regulates Cortical .beta.-Adrenoceptors in the Rat".
Buckett et al., British Pharmacol. Soc., Oral Communication, Dec. 19, 1986 "BTS 524, A Monoamine Uptake Inhibitor Exhibiting Potent Actions in Models Predictive of Potential Antidepressant Activity".
Luscombe et al., Int'l Symp on Antidepressants, Jerusalem, Apr. 1987, "The Putative Antidepressant BTS 54 524 Induces Rapid and Potent Down-Regulation of Cortical .beta.-Adrenoceptors in the Rat: Contribution of Metabolites".
Buckett et al., New Concepts in Depression, vol. 2, pp. 167-172, "BTS 54 524--An Approach to a Rapidly Acting Antidepressant", 1987.
Buckett et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988, vol. 12 pp. 575-584, "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), a New Antidepressant which Induces Rapid Noradrenergic Down-Regulation".
King et al., Br. J. Clin. Pharmac, 1988, vol. 26, pp. 607-611, "Clinical pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant, in healthy volunteers".
Manna et al., Int. Clin. Psychopharmacol. 1989, Jan. 4, suppl. 1, pp. 81-88, Double-Blind Controlled Study on the Clinical Efficacy and Safety of Fluoxetine vs. Clomipramine in the Treatment of Major Depressive Disorders.
Fernstrom et al, M.H. Chronic imipramine treatment and weight gain. Psychiatry Res 17. 269-275 (1986).
Haskell et al, D.S. Doxepin or diazepam for anxious and anxious-depressed outpatients. J. Clin. Psychiatry 39: 135-139 (1978).
Feighner et al, J.P. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J. Clin. Psychiatry 46: 20-25 (1985).
Nakra et al, B.R.S. Carbohydrate craving and weight gain with maprotiline. Psychosomatics 27: 376-381 (1986).
Orzack et al, M.H. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiol 15: 28-30 (1986).
Levitt et al, A. J. The effect of desipramine on body weight in depression. J. Clin. Psychiatry 40: 27-28 (1987).
Wurtman et al, J.J. Drugs that enhance central serotonergic transmission diminished elective carbohydrate consumption by rats. Life Sci 24: 895-904 (1979).
Wurtman et al, J.J. Carbohydrate craving in obese people: supression by treatment affecting serotonergic transmission. Int. J. Eat Disord 1: 2-15 (1981).
Blundell et al, J. E. On the Mechanism of Action of Dexfenfluramine: Effect on Alliesthesia and Appetite Motivation in Lean and Obese Subjects. Clinical Neuropharmacology vol. 11, suppl 1 (1988) pp. S122-S134.
Rozen et al, R. Permanent Administration of d-Fenfluramine in Rats: Paradoxical Effects. Clinical Neuropharmacology vol. 11, Suppl 1 (1988) pp. S105-S112.
Campbell et al, D. B. Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration. Clinical Neuropharmacology vol. 11 Suppl (1988) pp. S160-S172.
Turner P. Human Implications of Animal Experiments-- Lessons from Dexfenfluramine. Clinical Neuropharmacology vol. 11 Suppl 1 (1988) pp. S113-S120.
Richelson et al, E. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmcol. 104: 277-286 (1984).
Hall et al, H. Effects of antidepressant drugs on different receptors in the brain. Eur. J. Pharmacol. 70: 393-407 (1981).
Richardson et al, J. W. Antidepressants: a clinical update for medical practitioners. Mayo Clin. Proc. 59: 330 -337 (1984).
Richelson et al, E. Antagonism by Antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther. 230: 94-102 (1984).
Berken et al, G. H. Weight gain: a side effect of tricyclic antidepressants. J Affective Dis. 7: 133-138 (1984).
Robinson et al, D. S. A comparison of trazodone, amoxapine, and maprotiline in the treatment of endogenous depression: results of a multicenter study. Curr. Ther. Res. Clin. Exp. 35: 549-560 (1984).
Stern et al, S. L. Lack of weight gain under desipramine. Biol. Psychiatry 22: 796-797 (1987).
Benfield et al, P. Fluoxetine. Drugs 32: 481-508 (1986).
Fernstrom et al, M. H. Resting metabolic rate is reduced in patients treated with antidepressants. Biol Psychiatry 20: 692-695 (1985).
Cheetham et al, S. C. Inhibition of [.sup.3 H]-paroxetine binding by sibutramine, its metabolites and other antidepressants correlates with inhibition of [.sup.3 H]-5-HT uptake. Brit. J. Pharm vol. 101 515P (1990).
Luscombe et al, G. The contribution of metabolites to the rapid and potent down-regulation of rat cortical .beta.-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology vol. 28 pp. 129-134 (1989).
Brady, Kathleen T. "Weight Gain Associated Wtih Psychotropic Drugs." Southern Medical Journal, vol. 82, No. 5 (May 1989), pp. 611-617.
Hall, John "Fluoxetine: Efficacy Against Placebo and by Dose-An Overview." British Journal of Psychiatry, suppl. 3, (1988), pp. 59-63.
Altamura et al, A. C. "the Evidence of 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression." British Journal of Psychiatry, suppl. 3, (1988), pp. 109-112.
Sommi et al, R. W. "Fluoxetine: A Serotonin-specific, Second-generation Antidepressant." Pharmacotherapy, vol. 7, No. 1 (1987), pp. 1-15.
Ferguson, James M. "Fluoxetine-Induced Weight Loss in Overweight, Nondepressed Subjects." Am J Psychiatry, vol. 143, No. 11 (1986), pp. 1496.
Stuppack et al, Ch. "First Results of an Open Phase II Study with the Antideprssant Paroxetine." Pharmacopsychiat. (1988), pp. 369-370.
Warrington et al, S. J. "Cardiovascular (ECG and systoli
Cintins Marianne M.
The Boots Company (USA), Inc.
Travers Russell
LandOfFree
Treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739929